Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
(Redirected from Glycine-tRNA ligase)
Protein-coding gene in the species Homo sapiens
Glycine—tRNA ligase also known as glycyl–tRNA synthetase is an enzyme that in humans is encoded by the GARS1gene.
Function
This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases.
This enzyme belongs to the family of ligases, to be specific those forming carbon-oxygen bonds in aminoacyl-tRNA and related compounds. The systematic name of this enzyme class is glycine:tRNAGly ligase (AMP-forming). Other names in common use include glycyl-tRNA synthetase, glycyl-transfer ribonucleate synthetase, glycyl-transfer RNA synthetase, glycyl-transfer ribonucleic acid synthetase, and glycyl translase. This enzyme participates in glycine, serine and threonine metabolism and aminoacyl-trna biosynthesis.
Interactions
Glycyl-tRNA synthetase has been shown to interact with EEF1D. Mutant forms of the protein associated with peripheral nerve disease have been shown to aberrantly bind to the transmembrane receptor proteins neuropilin 1 and Trk receptors A-C.
Clinical relevance
Glycyl-tRNA synthetase has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis.
The peripheral nerve diseases Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) have been liked to dominant mutations in GARS. CMT2D usually manifests during the teenage years, and results in muscle weakness predominantly in the hands and feet. Two mouse models of CMT2D have been used to better understand the disease, identifying that the disorder is caused by a toxic gain-of-function of the mutant glycine-tRNA ligase protein. The CMT2D mice display peripheral nerve axon degeneration and defective development and function> of the neuromuscular junction.
Sang Lee J, Gyu Park S, Park H, Seol W, Lee S, Kim S (Feb 2002). "Interaction network of human aminoacyl-tRNA synthetases and subunits of elongation factor 1 complex". Biochemical and Biophysical Research Communications. 291 (1): 158–64. doi:10.1006/bbrc.2002.6398. PMID11829477.
Fraser MJ (May 1963). "Glycyl-RNA synthetase of rat liver: partial purification and effects of some metal ions on its activity". Canadian Journal of Biochemistry and Physiology. 41 (5): 1123–33. doi:10.1139/o63-128. PMID13959340.
Mudge SJ, Williams JH, Eyre HJ, Sutherland GR, Cowan PJ, Power DA (Mar 1998). "Complex organisation of the 5'-end of the human glycine tRNA synthetase gene". Gene. 209 (1–2): 45–50. doi:10.1016/S0378-1119(98)00007-9. PMID9524218.
Sang Lee J, Gyu Park S, Park H, Seol W, Lee S, Kim S (Feb 2002). "Interaction network of human aminoacyl-tRNA synthetases and subunits of elongation factor 1 complex". Biochemical and Biophysical Research Communications. 291 (1): 158–64. doi:10.1006/bbrc.2002.6398. PMID11829477.
Del Bo R, Locatelli F, Corti S, Scarlato M, Ghezzi S, Prelle A, Fagiolari G, Moggio M, Carpo M, Bresolin N, Comi GP (Mar 2006). "Coexistence of CMT-2D and distal SMA-V phenotypes in an Italian family with a GARS gene mutation". Neurology. 66 (5): 752–4. doi:10.1212/01.wnl.0000201275.18875.ac. PMID16534118. S2CID1143879.
James PA, Cader MZ, Muntoni F, Childs AM, Crow YJ, Talbot K (Nov 2006). "Severe childhood SMA and axonal CMT due to anticodon binding domain mutations in the GARS gene". Neurology. 67 (9): 1710–2. doi:10.1212/01.wnl.0000242619.52335.bc. PMID17101916. S2CID16491162.